Navigation Links
Therapy that heats and destroys bone tumors eases patients' pain
Date:6/2/2013

(CHICAGO) Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists. Results of a clinical trial on the new therapy, presented by a researcher at Jefferson's Kimmel Cancer Center, is being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

Mark Hurwitz, MD, Director of Thermal Oncology for the Department of Radiation Oncology at Thomas Jefferson University and Hospital reported that the treatment, magnetic resonance image-guided focused ultrasound (MRIgFU) ablation therapy, significantly reduced pain in 67 percent of patients who received the treatment. The device, known as ExAblate, uses numerous small ultrasound beams designed to converge on a tumor within bone, heat it and destroy it.

"Pain is a common, often debilitating symptom of the spread of cancer to bones. We are pleased to now have a second therapy that can improve a patient's enjoyment of life," says Dr. Hurwitz, who led the clinical trial. A number of cancers spread to bones, and a substantial proportion of patients live for years with these metastases, which can have a profound impact on a patient's quality of life, he adds.

The findings of the trial led to approval of ExAblate last October by the U.S. Food and Drug Administration as second-line therapy for palliation of painful metastatic bone tumors. The first-line therapy is typically radiotherapy.

"The response to ExAblate was as good as radiotherapy, which was notable because it is very unusual to see a second-line treatment with a response rate that is as high as first-line therapy," Dr. Hurwitz says.

He added that use of ExAblate offers several advantages compared to other ablative therapies. "It is non-invasive and provides more detailed anatomic information so that we can visualize the complete beam path to make sure that critical structures such as vessels and nerves are not in the way," Dr. Hurwitz says. "We are also able to monitor the temperature in the tumor as well as in nearby normal tissues so that we do not inadvertently heat normal organs and tissues."

ExAblate has also been approved for treatment of uterine fibroids.

The study led by Dr. Hurwitz is a multicenter, randomized and placebo-controlled phase three clinical trial. The 142 patients enrolled could either not undergo, or had not responded to, radiation treatment.

Three months after ExAblate therapy, 67 percent of treated patients reported significant improvement in pain, compared to 21 percent in the placebo arm. They typically rated their pain as "much improved" or "very much improved," Dr. Hurwitz says. A quality of life assessment also measured significant improvement.

"The treatment is given just once, and a response occurs within days," he says. "There are a lot of patients who could potentially benefit from MR guided focused ultrasound."


'/>"/>

Contact: Danielle Servetnick
danielle.servetnick@jefferson.edu
215-955-2238
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. MGH-led studies shed new light on targeted lung cancer therapy
2. Ayurveda Training in Marma Therapy, Basti, Abhyanga Massage, Swedana, and Ayurvedic Facial Offered in 2013 by the Leading Ayurvedic School in the United States
3. North American Seminars Introduces Responsible CME, a Program That Combined Live Physical Therapy Continuing Education with Online Continuing Education Courses
4. Mainz University obtains new CRC Nanodimensional polymer therapeutics for tumor therapy
5. New therapy is tolerable in lung cancer
6. Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Sixth Annual One Day Sale on Gift Certificates Will Take Place on June 19, 2013
7. Gene Therapy May Protect Against Flu Pandemics
8. Talk Therapy Can Ease Depression, But No Single Type Deemed Best
9. Avatar therapy helps silence voices in schizophrenia
10. Radiotherapy remains the treatment of first choice for high-risk low-grade glioma
11. Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... ... , drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos ... cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
(Date:2/17/2017)... CA (PRWEB) , ... February 17, 2017 , ... ... focus on foundational and sustainable systems change designed to further positively impact the ... “The Board of Trustees has long considered it our duty to seriously consider ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... , **An FDAnews Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 ... questions manufacturers should be asking before selecting an FDA approval pathway? , ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one of ... the 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management ... recognized across multiple award categories, highlighting four of the organization’s current programs:, ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 16, 2017 Quest Diagnostics (NYSE: ... services, today announced that it has been named one ... Fortune. The annual survey designated Quest ... "Health Care: Pharmacy and Other Services" industry to attain ... company to attain the designation. This is the second ...
(Date:2/16/2017)... STAMFORD, Conn. , Feb. 16, 2017 The ... to the 2017 Best Place to Work in ... . This is the third year in a row that ... places this year to earn the number-two spot in 2017. ... and maintaining workplace excellence. The winners were determined through a ...
(Date:2/16/2017)... Feb. 16, 2017 Summary Provides understanding ... by the worlds leading healthcare companies. ... Description The Global Allergy Partnering Terms and ... and agreements entered into by the world,s leading healthcare companies. ... by value - Deals listed by company A-Z, industry sector, ...
Breaking Medicine Technology: